Back to Search
Start Over
Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development.
- Source :
- Pharmaceutical Research; Jul2022, Vol. 39 Issue 7, p1321-1341, 21p
- Publication Year :
- 2022
-
Abstract
- Purpose: More than 15 years have passed since the first description of the unbound brain-to-plasma partition coefficient (K<subscript>p,uu,brain</subscript>) by Prof. Margareta Hammarlund-Udenaes, which was enabled by advancements in experimental methodologies including cerebral microdialysis. Since then, growing knowledge and data continue to support the notion that the unbound (free) concentration of a drug at the site of action, such as the brain, is the driving force for pharmacological responses. Towards this end, K<subscript>p,uu,brain</subscript> is the key parameter to obtain unbound brain concentrations from unbound plasma concentrations. Methods: To understand the importance and impact of the K<subscript>p,uu,brain</subscript> concept in contemporary drug discovery and development, a survey has been conducted amongst major pharmaceutical companies based in Europe and the USA. Here, we present the results from this survey which consisted of 47 questions addressing: 1) Background information of the companies, 2) Implementation, 3) Application areas, 4) Methodology, 5) Impact and 6) Future perspectives. Results and conclusions: From the responses, it is clear that the majority of the companies (93%) has established a common understanding across disciplines of the concept and utility of K<subscript>p,uu,brain</subscript> as compared to other parameters related to brain exposure. Adoption of the K<subscript>p,uu,brain</subscript> concept has been mainly driven by individual scientists advocating its application in the various companies rather than by a top-down approach. Remarkably, 79% of all responders describe the portfolio impact of K<subscript>p,uu,brain</subscript> implementation in their companies as 'game-changing'. Although most companies (74%) consider the current toolbox for K<subscript>p,uu,brain</subscript> assessment and its validation satisfactory for drug discovery and early development, areas of improvement and future research to better understand human brain pharmacokinetics/pharmacodynamics translation have been identified. [ABSTRACT FROM AUTHOR]
- Subjects :
- DRUG discovery
DRUG development
MICRODIALYSIS
PHARMACODYNAMICS
PHARMACOKINETICS
Subjects
Details
- Language :
- English
- ISSN :
- 07248741
- Volume :
- 39
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Pharmaceutical Research
- Publication Type :
- Academic Journal
- Accession number :
- 158365599
- Full Text :
- https://doi.org/10.1007/s11095-022-03246-6